MLH1 and neoplasm: Multiple studies have evaluated and identified high degrees of resistance from MLH1, MSH2, and MSH6 deficient tumor cell lines to temozolomide (Friedman et al., 1997; Taverna et al., 2000; Nguyen et al., 2014).